Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 670.5 JPY 0.39% Market Closed
Market Cap: 606.7B JPY
Have any thoughts about
Santen Pharmaceutical Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Santen Pharmaceutical Co Ltd stock under the Base Case scenario is 2 142.23 JPY. Compared to the current market price of 1 670.5 JPY, Santen Pharmaceutical Co Ltd is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
2 142.23 JPY
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Santen Pharmaceutical Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Santen Pharmaceutical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Santen Pharmaceutical Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Santen Pharmaceutical Co Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Santen Pharmaceutical Co Ltd

Provide an overview of the primary business activities
of Santen Pharmaceutical Co Ltd.

What unique competitive advantages
does Santen Pharmaceutical Co Ltd hold over its rivals?

What risks and challenges
does Santen Pharmaceutical Co Ltd face in the near future?

Summarize the latest earnings call
of Santen Pharmaceutical Co Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Santen Pharmaceutical Co Ltd.

Provide P/S
for Santen Pharmaceutical Co Ltd.

Provide P/E
for Santen Pharmaceutical Co Ltd.

Provide P/OCF
for Santen Pharmaceutical Co Ltd.

Provide P/FCFE
for Santen Pharmaceutical Co Ltd.

Provide P/B
for Santen Pharmaceutical Co Ltd.

Provide EV/S
for Santen Pharmaceutical Co Ltd.

Provide EV/GP
for Santen Pharmaceutical Co Ltd.

Provide EV/EBITDA
for Santen Pharmaceutical Co Ltd.

Provide EV/EBIT
for Santen Pharmaceutical Co Ltd.

Provide EV/OCF
for Santen Pharmaceutical Co Ltd.

Provide EV/FCFF
for Santen Pharmaceutical Co Ltd.

Provide EV/IC
for Santen Pharmaceutical Co Ltd.

Show me price targets
for Santen Pharmaceutical Co Ltd made by professional analysts.

What are the Revenue projections
for Santen Pharmaceutical Co Ltd?

How accurate were the past Revenue estimates
for Santen Pharmaceutical Co Ltd?

What are the Net Income projections
for Santen Pharmaceutical Co Ltd?

How accurate were the past Net Income estimates
for Santen Pharmaceutical Co Ltd?

What are the EPS projections
for Santen Pharmaceutical Co Ltd?

How accurate were the past EPS estimates
for Santen Pharmaceutical Co Ltd?

What are the EBIT projections
for Santen Pharmaceutical Co Ltd?

How accurate were the past EBIT estimates
for Santen Pharmaceutical Co Ltd?

Compare the revenue forecasts
for Santen Pharmaceutical Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Santen Pharmaceutical Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Santen Pharmaceutical Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Santen Pharmaceutical Co Ltd compared to its peers.

Compare the P/E ratios
of Santen Pharmaceutical Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Santen Pharmaceutical Co Ltd with its peers.

Analyze the financial leverage
of Santen Pharmaceutical Co Ltd compared to its main competitors.

Show all profitability ratios
for Santen Pharmaceutical Co Ltd.

Provide ROE
for Santen Pharmaceutical Co Ltd.

Provide ROA
for Santen Pharmaceutical Co Ltd.

Provide ROIC
for Santen Pharmaceutical Co Ltd.

Provide ROCE
for Santen Pharmaceutical Co Ltd.

Provide Gross Margin
for Santen Pharmaceutical Co Ltd.

Provide Operating Margin
for Santen Pharmaceutical Co Ltd.

Provide Net Margin
for Santen Pharmaceutical Co Ltd.

Provide FCF Margin
for Santen Pharmaceutical Co Ltd.

Show all solvency ratios
for Santen Pharmaceutical Co Ltd.

Provide D/E Ratio
for Santen Pharmaceutical Co Ltd.

Provide D/A Ratio
for Santen Pharmaceutical Co Ltd.

Provide Interest Coverage Ratio
for Santen Pharmaceutical Co Ltd.

Provide Altman Z-Score Ratio
for Santen Pharmaceutical Co Ltd.

Provide Quick Ratio
for Santen Pharmaceutical Co Ltd.

Provide Current Ratio
for Santen Pharmaceutical Co Ltd.

Provide Cash Ratio
for Santen Pharmaceutical Co Ltd.

What is the historical Revenue growth
over the last 5 years for Santen Pharmaceutical Co Ltd?

What is the historical Net Income growth
over the last 5 years for Santen Pharmaceutical Co Ltd?

What is the current Free Cash Flow
of Santen Pharmaceutical Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Santen Pharmaceutical Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Santen Pharmaceutical Co Ltd

Current Assets 233.9B
Cash & Short-Term Investments 90.2B
Receivables 83.6B
Other Current Assets 60B
Non-Current Assets 200.3B
Long-Term Investments 24.6B
PP&E 72.2B
Intangibles 83.2B
Other Non-Current Assets 20.2B
Current Liabilities 89.9B
Accounts Payable 45.6B
Other Current Liabilities 44.3B
Non-Current Liabilities 37.6B
Long-Term Debt 32.6B
Other Non-Current Liabilities 4.9B
Efficiency

Earnings Waterfall
Santen Pharmaceutical Co Ltd

Revenue
304.3B JPY
Cost of Revenue
-125.2B JPY
Gross Profit
179.1B JPY
Operating Expenses
-140.2B JPY
Operating Income
38.9B JPY
Other Expenses
-12.1B JPY
Net Income
26.9B JPY

Free Cash Flow Analysis
Santen Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Santen Pharmaceutical Co Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

Santen Pharmaceutical Co Ltd's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Santen Pharmaceutical Co Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
90/100
Solvency
Score

Santen Pharmaceutical Co Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Santen Pharmaceutical Co Ltd

Wall Street analysts forecast Santen Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Santen Pharmaceutical Co Ltd is 2 145.06 JPY with a low forecast of 1 717 JPY and a high forecast of 2 730 JPY.

Lowest
Price Target
1 717 JPY
3% Upside
Average
Price Target
2 145.06 JPY
28% Upside
Highest
Price Target
2 730 JPY
63% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Santen Pharmaceutical Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Santen Pharmaceutical Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd

Country

Japan

Industry

Pharmaceuticals

Market Cap

594.1B JPY

Dividend Yield

2.04%

Description

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,229 full-time employees. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.

Contact

OSAKA-FU
Osaka
25F, Grand Front Osaka Tower A, 4-20, Ofuka-cho, Kita-ku
+81676648621.0
www.santen.co.jp

IPO

1963-11-04

Employees

4 229

Officers

President, CEO & Representative Director
Mr. Takeshi Ito
CFO & Corporate Officer
Mr. Kazuo Koshiji
COO, Corporate Officer & Director
Ms. Rie Nakajima
General Manager of Investor Relations Group
Ms. Kaori Itagaki
General Counsel & Chief Compliance Officer
Ms. Mika Masunari
Chief Communications Officer
Ms. Nobuko Kato
Show More
Senior Corporate Officer & Head of Corporate Development Division & Director
Mr. Satoshi Suzuki
Corp. Officer, Head of Sales and Head of Japan Sales & Marketing
Mr. Shinichi Teramachi
Corporate Officer & Head of China Product Development Department
Mr. Kenji Morishima
Global Head of Core Principle & Sustainability and Corporate Officer
Mr. Takahiro Morita
Show Less

See Also

Discover More
What is the Intrinsic Value of one Santen Pharmaceutical Co Ltd stock?

The intrinsic value of one Santen Pharmaceutical Co Ltd stock under the Base Case scenario is 2 142.23 JPY.

Is Santen Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 1 670.5 JPY, Santen Pharmaceutical Co Ltd is Undervalued by 22%.

Back to Top